

Flerie's portfolio company AnaCardio reports positive results from phase 1b study of AC01 in patients with heart failure and reduced ejection fraction, and announces SEK 205 million financing round

AnaCardio has successfully completed Part A of the phase 1b/2a GOAL-HF1 study of its novel, selective oral ghrelin receptor agonist in patients with heart failure. AC01 was well-tolerated, there was clear target engagement and exploratory pharmacodynamic measurements indicated increased contractility. This will be further evaluated in Part B of the ongoing trial, in the cohort expansion phase, due to start in early 2025.

In conjunction with this important clinical milestone, the company has completed a SEK 205 M Series A extension financing round, co-led by Novo Holdings, Pureos Bioventures and Sound Bioventures, with participation from current investors Flerie, Industrifonden and Fredrik and Ann-Helene Ljungström.

"We are pleased that given these encouraging results, AC01 can now move into the next phase of clinical development: We also welcome the new investors which further strengthens the syndicate. AnaCardio is now in an excellent position and one step closer to bringing a novel contractile agent to heart failure patients", commented Mark Quick, Partner at Flerie.

For more information:

Ted Fjällman, CEO
Email: ir@flerie.com

Flerie in brief

Flerie is an active long-term life science investor, with a broad and diversified portfolio of innovative companies based on pioneering science. We invest in product development and commercial growth opportunities globally alongside other leading investors, focusing predominantly on private companies that are otherwise difficult to access. Flerie's active ownership model, broad network and resources support and accelerate the development of the portfolio projects, creating value for shareholders. Flerie AB's ordinary share is listed on Nasdaq Stockholm with the ticker FLERIE. For further information please visit www.flerie.com

Attachments

[Flerie's portfolio company AnaCardio reports positive results from phase 1b study of AC01 in patients with heart failure and reduced ejection fraction, and announces SEK 205 million financing round](#)